首页> 外文期刊>Molecular and Cellular Biology >The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
【24h】

The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.

机译:肿瘤抑制因子p53和癌蛋白猿猴病毒40 T抗原与MDM2蛋白上的重叠域结合。

获取原文
           

摘要

The oncogene mdm2 has been found to be amplified in human sarcomas, and the gene product binds to the tumor suppressor p53. In this report, we describe the dissection of the MDM2-binding domain on p53 as well as the p53-binding domain on MDM2. We also demonstrate that the oncoprotein simian virus 40 T antigen binds to the product of cellular oncogene mdm2. We have constructed several N- and C-terminal deletion mutants of p53 and MDM2, expressed them in vitro, and assayed their in vitro association capability. The N-terminal boundary of the p53-binding domain on MDM2 is between amino acids 1 and 58, while the C-terminal boundary is between amino acids 221 and 155. T antigen binds to an overlapping domain on the MDM2 protein. On the other hand, the MDM2-binding domain of p53 is defined by amino acids 1 and 159 at the N terminus. At the C terminus, binding is progressively reduced as amino acids 327 to 145 are deleted. We determined the effect of human MDM2 on the transactivation ability of wild-type human p53 in the Saos-2 osteosarcoma cell line, which does not have any endogenous p53. Human MDM2 inhibited the ability of human p53 to transactivate the promoter with p53-binding sites. Thus, human MDM2 protein, like the murine protein, can inactivate the transactivation ability of human p53. Interestingly, both the transactivation domain and the MDM2-binding domain of p53 are situated near the N terminus. We further show that deletion of the N-terminal 58 amino acids of MDM2, which eliminates p53 binding, also abolishes the capability of inactivating p53-mediated transactivation. This finding suggests a correlation of in vitro p53-MDM2 binding with MDM2's ability in vivo to interfere with p53-mediated transactivation.
机译:已经发现致癌基因mdm2在人肉瘤中被扩增,并且基因产物与肿瘤抑制因子p53结合。在此报告中,我们描述了p53上MDM2结合域以及MDM2上p53结合域的解剖。我们还证明了癌蛋白猿猴病毒40 T抗原与细胞癌基因mdm2的产物结合。我们已经构建了p53和MDM2的几个N和C端缺失突变体,在体外表达它们,并测定了它们的体外结合能力。 MDM2上p53结合结构域的N末端边界在氨基酸1和58之间,而C末端边界在氨基酸221和155之间。T抗原与MDM2蛋白上的重叠结构域结合。另一方面,p53的MDM2结合结构域由N末端的氨基酸1和159定义。在C末端,随着氨基酸327至145的缺失,结合逐渐减少。我们确定了人类MDM2对Saos-2骨肉瘤细胞系中野生型人类p53的反式激活能力的影响,而Saos-2骨肉瘤细胞系没有任何内源性p53。人MDM2抑制人p53激活具有p53结合位点的启动子的能力。因此,人MDM2蛋白,如鼠蛋白,可以失活人p53的反式激活能力。有趣的是,p53的反式激活域和MDM2结合域都位于N末端附近。我们进一步表明删除MDM2的N端58个氨基酸,消除了p53结合,也消除了灭活p53介导的反式激活的能力。该发现表明体外p53-MDM2结合与MDM2在体内干扰p53介导的反式激活的能力有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号